Prime® Education
Free CME and Other Educational Activities
Advances in PAH: Optimizing Care with the Latest Guidelines and Treatment Approaches
Prime® Education CME/CE Credit (1-hr)
Prime Code: 72251
Expiration Date: 9/29/26
Intended Audience: Pulmonologists, cardiologists and their teams of nurse practitioners (NPs), physician assistants (PAs), nurses, and pharmacists
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease marked by vascular remodeling and right ventricular dysfunction, leading to significant morbidity and mortality if not promptly recognized and managed. Early diagnosis, comprehensive risk assessment, and timely treatment escalation are critical to improving patient outcomes.
Watch this video led by a renowned PAH expert for an update on the latest guidelines and clinical evidence, newest treatment approaches, and actionable strategies to help you optimize care for patients with PAH.
To complement your learning, you'll also receive access to a downloadable Guide to PAH Essentials-a concise, quick-reference resource designed to support accurate diagnosis, effective risk stratification, and evidence-based treatment escalation to achieve therapeutic goals.
Don't miss this opportunity to sharpen your PAH management skills and elevate the care you provide.
PH Associated With ILD Care: The Latest Advances in Diagnosis and Treatment
Prime® Education CME/CE Credit (1-hr)
Prime Code: 119241
Expiration Date: 12/31/26
Intended Audience: Managed care professionals, including pharmacy directors, medical directors, pharmacists, physician assistants, and medication therapy management nursing directors working in managed care organizations and specialty pharmacy
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is a distinct form of pulmonary hypertension. PH in ILD drives a greater degree of functional impairment, healthcare utilization, and mortality than does underlying lung disease alone. A lack of PH-ILD-specific pharmacologic options had historically led to off-label use of medications for this condition, despite a paucity of evidence supporting their use in this patient population. The first FDA approval of a PH-ILD therapy gives prescribers the ability to move towards a more uniform evidence-based treatment approach.
This CME-accredited publication in the Journal of Managed Care and Specialty Pharmacy (JMCP) will discuss:
Definition, scope, and burden of PH-ILD
Complex pathophysiology
Diagnostic challenges
Data for therapies that have been used off-label in PH-ILD patients
Pharmacologic advances and the resulting implications for managed care
Latest guidelines
Pulmonary Arterial Hypertension Unveiled: From Pathways to Presentation
Prime® Education CME/CE Credit (0.5hr)
Prime Code: 72253
Expiration Date: 11/18/26
Intended Audience: Pulmonologists and their clinical care teams of advanced practice providers (NPs, PAs), nurses, and pharmacists
Effective evaluation and management of pulmonary arterial hypertension (PAH) begin with a deep understanding of its underlying mechanisms, disease classification, and clinical manifestations. Recognizing the pathways that drive disease progression, and the often subtle signs and symptoms of PAH, is essential to improving early diagnosis and patient outcomes.
Tune in to the first video podcast of our three-part series, developed from a live symposium presented at CHEST, as leading experts break down the fundamentals of PAH, exploring its classification, key molecular pathways, and clinical presentation through real-world insights and evidence-based discussion.
Stream the podcast video or the audio-only version and access downloadable evidence summaries and a point-of-care tool to support early recognition and optimal management of PAH in your daily practice.
Advancing the Evaluation of PAH: From Diagnosis to Long-Term Monitoring
Prime® Education CME/CE Credit (0.5hr)
Prime Code: 72253
Expiration Date: 11/18/26
Intended Audience: Pulmonologists and their clinical care teams of advanced practice providers (NPs, PAs), nurses, and pharmacists
Effective management of pulmonary arterial hypertension (PAH) depends on accurate diagnosis, risk assessment, and ongoing monitoring to guide therapy and improve patient outcomes. Early and precise identification through hemodynamic evaluation, combined with evidence-based risk stratification, allows clinicians to tailor management strategies and detect disease progression before clinical deterioration occurs.
Tune in to this second video podcast of our three-part series, developed from a live symposium presented at CHEST, as leading experts discuss best practices for the diagnostic workup of suspected PAH, approaches to comprehensive risk assessment, and practical methods for ongoing monitoring and follow-up.
Stream the podcast video or the audio-only version and access downloadable clinical resources and point-of-care tools to support timely diagnosis, risk-based treatment decisions, and long-term management of patients with PAH.
Maximizing Outcomes in PAH: Targeted Therapies and Evidence-Based Treatment Strategies
Prime® Education CME/CE Credit (0.25hr)
Prime Code: 72253
Expiration Date: 11/18/26
Intended Audience: Pulmonologists and their clinical care teams of advanced practice providers (NPs, PAs), nurses, and pharmacists
Effective management of pulmonary arterial hypertension (PAH) relies on a clear understanding of the key pathogenic pathways and the use of targeted, guideline-directed therapies. Optimizing treatment requires careful selection, combination, and escalation of available therapies to improve outcomes and maintain patient function over time.
Tune in this final video podcast of our three-part series, developed from a live symposium presented at CHEST, as leading experts review the major PAH pathways, discuss currently approved targeted therapies, and highlight evidence-based strategies for implementing guideline-recommended treatment and escalation.
Stream the podcast video or the audio-only version and access downloadable clinical resources and point-of-care tools to support pathway-directed therapy, risk-based decision-making, and ongoing management of patients with PAH.